Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

The results of first randomised, double-blind, placebo controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 are reported. The study was terminated before attaining the prespecified sample size. In the intention-to-treat population, the primary endpoint of time to clinical improvement was not significantly different between groups, but was numerically shorter in the remdesivir group than the control group, particularly in those treated within 10 days of symptom onset. Ongoing studies with larger sample sizes will continue to inform the understanding of the effect of remdesivir on COVID-19. Furthermore, strategies to enhance the antiviral potency of remdesivir (eg, higher-dose regimens, combination with other antivirals, or SARS-CoV-2 neutralising antibodies) should also be studied.

Tags: